M etabolic syndrome is characterized by the presence of Ն3 of the following characteristics: abdominal obesity, elevated triglyceride concentrations, low high-density lipoprotein (HDL), high blood pressure, and elevated fasting glucose. On the basis of estimates from the third National Health and Nutrition Examination Survey, the prevalence of metabolic syndrome is 44% among adults in the United States Ͼ50 years of age. 1 Metabolic syndrome is associated with increased risk of type 2 diabetes mellitus (T2DM) and cardiovascular disease. Evidence from the West of Scotland Study indicates that men with metabolic syndrome had 1.7-fold increased risk of a cardiovascular event and 3.5-fold increased risk of developing diabetes. 2 The mechanisms that cause metabolic syndrome are poorly understood but likely involve insulin resistance, which is associated closely with abdominal obesity and is an independent risk factor for cardiovascular disease. Indeed, a large body of evidence supports the notion that adipose tissue factors may mediate several of the metabolic changes that occur with metabolic syndrome. 3 Metabolic syndrome, along with its individual components, is likely to be under the influence of both environmental and genetic factors.
To localize genes contributing to T2DM, cardiovascular disease, and related traits, including obesity and metabolic syndrome, we conducted a genome-wide linkage analysis in large Old Order Amish families from Lancaster County, Pa. 4, 5 Evidence for linkage with T2DM, impaired glucose tolerance, or impaired fasting glucose was observed on chromosome 1q21-q24 (logarithm of oddsϭ2. 35 ; PϽ0.0005). 5 This region is a gene-rich region that includes Ն530 genes. Excellent positional candidate genes include APOA (apolipoprotein A2), 6 PBX1 (pre-B-cell leukemia transcription factor 1), 7 slc19a2 (solute carrier family 19 [thiamine transporter] member 2), 8 INSRR (insulin receptor-related receptor gene), 9 KCNJ9 and KCNJ10 (potassium inwardly-rectifying channel, subfamily J, members 9 and 10), 10 PEA 15 (phosphoprotein enriched in astrocytes 15), 11 RXRG (the ␥ subunit of the retinoid X receptor), 12 CRP (C-reactive protein), 13 HYPLIP1 (familial combined hyperlipidemia gene), 14 CASQ1 (calsequestrin 1), 15, 16 VAMP 4 (vesicle-associated membrane protein 4; 17 M Sabra, S Ott, J Lee, JR O'Connell, BD Mitchell, AR Shuldiner, unpublished data, 2004), USF1 (upstream stimulatory factor 1), 18, 19 and LMNA (lamin A/C). 20 This region is approximately 160 to 180 cM from p-telomere and corresponds to a region of chromosome 1 that has been linked to T2DM in several other populations, including Pima Indians, 21 Utah Mormons, 22 British whites, 23 French whites, 24 and Chinese. 25 Familial partial lipodystrophy is a condition associated with severe insulin resistance, diabetes, dyslipidemia, and atherosclerosis, 26 making LMNA an excellent positional candidate gene for metabolic syndrome, T2DM, and related traits. LMNA, located on chromosome 1q21.2, encodes a nuclear envelope protein that exists as a heterodimer of lamin A and lamin C and is expressed in several cell types including liver, fat, muscle, and pancreas. 27 The gene contains 12 coding exons. Alternative splicing within exon 10 of LMNA results in coding either the lamin A or lamin C protein. Mutations in LMNA have been shown to result in a number of disorders, including Emery-Dreifuss muscular dystrophy (Online Mendelian Inheritance in Man [OMIM] 181350), 28, 29 dilated cardiomyopathy with conduction defects (OMIM 115200), 30 familial partial lipodystrophy (OMIM 151660), [31] [32] [33] [34] mandibuloacral dysplasia (MAD; OMIM 248370), 35 Huchinson-Gilford progeria (OMIM 176670), 36 -38 and autosomal dominant and recessive forms of Charcot Marie tooth disease (OMIM 605588). [39] [40] The mechanism whereby mutations in LMNA lead to these diverse phenotypes is presently unknown.
The aim of this study was to search for novel sequence variation in LMNA and to determine whether variants in this gene influence susceptibility to metabolic syndrome and its constituent components. We sequenced LMNA in 18 Amish subjects diagnosed previously with T2DM from the Amish Family Diabetes Study (AFDS). These individuals were selected from families showing evidence for linkage to the region of interest on chromosome 1. We then performed association and haplotype analyses in the full AFDS cohort to determine whether the polymorphisms identified in LMNA are associated with diabetes, metabolic syndrome, and related traits in the Amish. We found that the polymorphism H565H in exon 10 was associated with metabolic syndrome as well as with higher fasting triglyceride and lower HDL-cholesterol concentrations, suggesting that LMNA variation may confer modest susceptibility for development of metabolic syndrome and dyslipidemia in the Amish.
Research Design and Methods

Subjects
Subject recruitment for the AFDS began in 1995. Details of the AFDS design, recruitment, phenotyping, and pedigree structures have been described previously. 4 Briefly, probands were defined as individuals with previously diagnosed diabetes with the age at diagnosis between 35 and 65 years. All first-and second-degree family members Ն18 years of age were recruited around the diabetic probands. If another diabetic individual was identified in the family (eg, aunt or uncle), the family was expanded further to include the first-and second-degree relatives of that individual Ն18 years of age. The AFDS participants were divided into 45 families, although all of these families can be joined into a single pedigree by including ancestors going back 12 to 14 generations. [41] [42] None of the subjects had known muscular dystrophy, structural or cardiac conduction abnormalities, progeria, or familial partial lipodystrophy, conditions that have been associated previously with mutations in the LMNA gene.
Data regarding medical, social, and family history were obtained during an interview at our Amish Research Clinic or the subject's home. Height, weight, and waist circumference were measured. Body mass index (BMI) was calculated as weight (kilograms) divided by height squared (m 2 ) to estimate total adiposity. Waist circumference was measured by a single observer. For this procedure, subjects were asked to remove any unnecessary clothing. The subject stood erect with the abdomen relaxed, arms at sides, and feet together. The measurer faced the subject and placed an inelastic tape around him/her in a horizontal plane at the level of the natural waist, which is the narrowest part of the torso, as seen from the anterior aspect. In obese subjects, the smallest horizontal circumference was measured in the area between the ribs and iliac crest. The measurement was taken at the end of a normal expiration, without the tape compressing the skin, and recorded to the nearest 0.1 cm. Blood pressure was measured in the left arm with standard sphygmomanometer while the subject was seated after 10 minutes of rest. A single observer made duplicate measurements, and the average of these was recorded.
Fasting lipid profile (HDL-cholesterol and triglyceride concentrations) was assayed by Quest Diagnostics (Baltimore, Md; interassay coefficient of variation 5.0% for HDL-cholesterol; 1.6% for triglycerides). A 3-hour 75-g oral glucose tolerance test (OGTT) was performed on subjects with no previous history of diabetes. The T2DM diagnosis was defined on the basis of the OGTT using the plasma glucose criteria of the American Diabetes Association (2 hour glucose Ն11.1 mmol/L or fasting glucose Ն7 mmol/ L). Subjects were also considered to have diabetes if they were currently taking medications for diabetes treatment. Subjects were excluded if there was a history of type 1 diabetes. Additionally, we defined impaired glucose homeostasis (IGH) as 2 hour glucose Ͼ7.7 mmol/L and Ͻ11.1 mmol/L or fasting glucose Ն6.1 mmol/L and Ͻ7 mmol/L. Metabolic syndrome was defined using the National Cholesterol Education Program (NCEP) ATP III guidelines. 43 It is characterized by the presence of Ն3 of the following characteristics: abdominal obesity (waist circumference Ͼ102 cm for men and Ͼ88 cm for women), elevated triglycerides (Ͼ1.68 mmol/L), low HDL (Ͻ1.03 mmol/L for men and Ͻ1.29 mmol/L for women), high blood pressure (Ն130/85 mm Hg), and elevated fasting glucose (Ͼ6.0 mmol/L). Clinical characteristics of Amish subjects are shown in Table 1 .
The mean age of diagnosis of diabetes in the AFDS cohort was 59.7Ϯ11.0 years (range 35 to 83 years), and the mean BMI was 28.8Ϯ5.2 kg/m 2 (range 16.4 to 40.7 kg/m 2 ). The 18 AFDS subjects selected for screening for mutations in LMNA in this study were individuals with diabetes who were members of different nuclear families that showed evidence for linkage to the area of interest on chromosome 1. The mean age of these 18 subjects was 61.3Ϯ12.3 years (range 49 to 90 years). The study was conducted in accordance with the human subject standards of the institutional review board of the University of Maryland, and informed consent was obtained from all subjects.
Laboratory Methods
Whole blood was collected from the subjects, and genomic DNA was isolated using Maxipreps according to the instructions of the manufacturer (Qiagen). All 12 exons as well as the exon-intron junctions of LMNA were amplified by polymerase chain reaction (PCR). Primers for DNA amplification and sequencing were derived using the published sequence for LMNA (GenBank AC007227; Table I , available online at http://atvb.ahajournals.org). DNA sequencing was performed using an Applied Biosystems 377 automated DNA sequencer (Perkin-Elmer). PCR products were sequenced in both directions, visually inspected, and compared with the GenBank sequence of human LMNA.
Genotyping was completed using an Orchid SNPstream UHT genotyping system (Orchid Bioscience). First, the target genomic sequences containing the single-nucleotide polymorphisms (SNPs) of interest were amplified in a 12-plex PCR reaction. After enzymatic clean-up, PCR products were subjected to an extension reaction using 5Ј-tagged extension primers and fluorescent dyelabeled terminators. In a thermal cycled extension step, the primers hybridized to the specific amplicons 1 base adjacent to the SNP site and were extended by 1 base at the 3Ј end with a fluorescently labeled nucleotide. These reaction products were transferred to an array plate, where each of the 12 extension products in the multiplex reaction was sorted by hybridization of the unique 5Ј-tag sequence to its complementary probe immobilized in a miniarray within each well. The Orchid SNPscope reader imaged the microarray plates. The 2-color detection allowed SNP detection by comparing signals from the 2 fluorescent dyes. The image signals were then transferred to genotyping software that translated the images of the arrays into genotype calls. The error rate on the basis of blind replicates was 0.1% to 2% for the SNPs examined in the present study.
Analysis
Before analysis, genotypes were checked for Mendelian consistency, and inconsistencies, which were detected in Ͻ0.5% of genotypes, were removed from analysis. Genotype frequencies of all SNPs were tested for consistency with Hardy-Weinberg expectations by the 2 test. We then followed a 2-tiered analytic approach, first performing association analyses with each SNP individually and then considering SNPs jointly as haplotypes.
Because mutations in LMNA have been associated previously with diabetes 20 and dyslipidemia, 44 we examined the relationship of LMNA polymorphisms identified in the Amish with the metabolic syndrome and its component traits. For the quantitative traits associated with metabolic syndrome (ie, glucose, obesity, and lipid levels), we estimated mean trait levels according to LMNA genotypes, whereas for the qualitative traits (metabolic syndrome, T2DM, and abnormal glucose tolerance), we compared disease prevalence across genotypes. Subjects currently taking insulin (nϭ27), ␤-hydroxy-␤-methylglutaryl coenzyme A reductase inhibitors or other lipid-lowering medications (nϭ7), aspirin (nϭ24), angiotensin-converting enzyme inhibitors, or other blood pressure-lowering agents (nϭ6), or estrogens (nϭ3) were excluded from analysis (nϭ63 subjects taking Ն1 of the above).
To account for the relatedness among family members, we used the measured genotype approach, 45 in which we estimated the likelihood of specific genetic models given the pedigree structure. For example, we compared the likelihood of a full model, which allowed for genotypicspecific means, to that of a nested model in which genotypic means were restricted to be equal to each other. Parameter estimates were obtained by maximum likelihood methods, and the significance of association was tested by likelihood ratio tests. Within each model, we simultaneously estimated the effects of age and sex. Triglyceride values were transformed by their natural logarithms (lns) to reduce skewness. All analyses were conducted using the Sequential Oligogenic Linkage Analysis Routines program. 46 The strength of linkage disequilibrium between all pair-wise combinations of SNPs and haplotypes were inferred for each individual using an expectation maximization algorithm implemented into the ZAPLO software program. 47 Additional association analyses were then performed treating each haplotype as a super-allele as described above.
Results
In sequence analysis of 18 relatively unrelated Amish T2DM subjects (36 alleles), we identified 6 SNPs, including c.141906GϾT and c.141889CϾT (intron 3); A287A (c.141253TϾC; exon 5); c.140353GϾA (intron 6); c.139418CϾT (intron 8); and H566H (c. 138747CϾT; exon 10). This exon 10 SNP is also designated as rs4641 and has been identified as GenBank No. X03444 C1908T previously. 40 Although this SNP is silent, it is of particular interest because it occurs at the last nucleotide in exon 10, where alternate splicing determines the relative amounts of lamin A and lamin C transcripts (Figure) . The exon 5 A287A (c.141253TϾC) SNP is also a silent mutation. The intronic SNPs do not predict any obvious functional sequelae.
The frequencies of the minor alleles at each of the 6 SNPs ranged from 0.05 to 0.35 ( Table 3 ). The distribution of genotypes for all SNPs was consistent with Hardy-Weinberg equilibrium. The degree of linkage disequilibrium was strong between the 2 intron 3 SNPs (r 2 ϭ0.93; DЈϭ1), moderate between the intron 3 SNPs and SNPs at exon 5, intron 6, and intron 8, and among the latter SNPs (r 2 ϭ0.45 to 0.84; DЈϭ0.94 to 1) and weaker between the exon 10 SNP and all others (r 2 ϭ0.02 to 0.12; DЈϭ0.35 to 1; see Table 3 ).
The prevalence rates for T2DM and IGH were 9.8% and 25.9%, respectively, in this sample. Allele and genotype frequencies did not differ between T2DM cases and controls for any of the 6 SNPs, nor was there evidence for association of any of the SNPs with the composite trait T2DM/IGH ( Table 2) . We examined the relationships between BMI and metabolic syndrome-related traits and LMNA sequence variants. Mean levels of obesity and lipid measures are also shown in Table 2 according to the exon 10 H566H (c.138747CϾT) genotype. Triglyceride concentrations were higher and HDL concentrations lower in subjects with the T allele (Pϭ0.004 and 0.03, respectively). There was also a significant association with metabolic syndrome as defined by NCEP ATP III guidelines (Pϭ0.017, odds ratio 1.43; CI 1.05 to 1.80).
Corresponding analyses of the exon 5 A287A (c.141253TϾC) SNP showed higher fasting glucose among those with the C allele than those with the TT genotype (Pϭ0.001). No significant association with obesity measures, lipid traits, or blood pressure was seen for this SNP. Analysis of the intronic SNPs showed no significant association with obesity, lipid traits, or metabolic syndrome (data not shown).
As a secondary analysis of the exon 10 variant H566H (c.138747CϾT), we evaluated whether the effects of the exon Schematic of the genomic structure of LMNA. LMNA is composed of 12 exons. Alternate splicing within exon 10 results in 2 distinct mRNA transcripts corresponding to lamin A (664 amino acids) and lamin C (572 amino acids). The mature protein lamin A/C functions as a heterodimer. Also shown are SNPs detected in our mutation screen and their locations. Note that 138747CϾT is a silent mutation in exon 10 at the alternate splice site. Promoter is not shown. NLS indicates nuclear location signal; UTR, untranslated region.
10 CT/TT genotype on metabolic syndrome and related traits differed between men and women or between younger or older individuals. There was little evidence that the genotype effect differed between men and women for any trait. For triglycerides, age-stratified analyses indicated that the genotype effect differed little between younger and older men, with the CT/TT genotype associated with a 3.3% and 3.6% increase in ln triglyceride levels in men younger and older than age 50, respectively. However, in women, the effect of the CT/TT genotype was restricted almost entirely to those Ն50 years of age; among these older women, being exposed to the T allele was associated with a 3.8% increase in ln triglyceride levels compared with only a 0.3% increase for women Ͻ50 years of age. This interaction effect did not achieve statistical significance (Pϭ0.17).
We next considered the possibility that haplotypes defined by allelic combinations at these 6 SNPs might show associations with either disease status or with quantitative trait levels. Because of marked linkage disequilibrium between markers (Table 3) , 2 most frequent haplotypes (C138747-T141253-C139418-G140353-C141889-T141906 and T138747-T141253-C139418-G140353-C141889-T141906) together accounted for Ͼ87% of the haplotypes in the Amish. The estimated frequencies of the first 2 most common haplotypes are 0.548292 and 0.327621, respectively. There were no significant differences in haplotype frequencies among subjects with T2DM or metabolic syndrome and controls, nor were there any differences in glucose, insulin, obesity, or lipid traits between haplotypes.
Discussion
Mutations in LMNA have been found in diseases involving muscle and fat cells and include Emery-Dreifuss muscular dystrophy, 28, 29 dilated cardiomyopathy with conduction defects, 30 familial partial lipodystrophy, [31] [32] [33] [34] MAD, 35 and Charcot Marie tooth disease, 39 -40 as well as premature aging. 36 -38 Familial partial lipodystrophy is associated with severe insulin resistance, diabetes, dyslipidemia, and atherosclerosis. 26 Our genome-wide scan in the Amish 5 and those of several others [21] [22] [23] [24] [25] provide strong evidence for the existence of Ն1 T2DM susceptibility genes on chromosome 1q21-q24, the region in which LMNA resides. These observations led us to sequence all of the exons and exon-intron boundaries of LMNA in subjects with diabetes from Amish families, providing evidence for linkage to chromosome 1q21-q24. Although our mutation screen detected 6 SNPs, none resulted in obvious alterations in protein structure, and none were associated with T2DM or IGH. We did not screen for mutations in regulatory regions or the entirety of all introns, and thus cannot rule out the possibility that significant mutations may be present in these regions. However, lack of association of any haplotype with T2DM or related traits make this possibility less likely. Thus, LMNA is unlikely to be the gene on chromosome 1q21-q24 detected through linkage analysis contributing to risk of T2DM.
Modest associations with a common variant in exon 10 of LMNA (H566H) have been shown to be associated with adipose tissue metabolism and obesity phenotypes. 48 -50 In Canadian Oji-Cree and Inuit, this variant was associated with BMI, waist-to-hip ratio, leptin, and body fat percentage. 48, 49 Additionally, this variant has been studied in a Japanese cohort 44 and in Pima Indians. 50, 51 In Pimas, no evidence for association of H566H with T2DM, BMI, total cholesterol, HDL-cholesterol triglycerides, or indices of insulin sensitivity and secretion was found. 51 However, Pimas with the T allele had significantly greater subcutaneous fat cell size. 50 In the Japanese cohort, this variant was associated with higher fasting insulin, triglyceride, total cholesterol concentrations, and lower HDL-cholesterol concentrations. 44 Amish individuals who were exposed to the T allele of the c.138747CϾT variant had higher triglyceride concentrations and lower HDL-cholesterol and were more likely to have the presence of metabolic syndrome. Thus, it is possible that this variant plays a modest role in modulating the metabolic syndrome, particularly lipid components.
Although this SNP encodes a silent mutation H566H, it is the terminal exonic nucleotide of exon 10, the site of alternate splicing for lamin A and C mRNA. This polymorphism could alter mRNA splicing and thus the relative amounts of lamin A and C mRNA and protein. Indeed, the silent LMNA G608G SNP has been shown to cause aberrant mRNA splicing and to cause Hutchinson-Gilford progeria. 36 In summary, screening of LMNA revealed 6 SNPs. One SNP, H566H (c.138747CϾT), showed significant association with metabolic syndrome and with lower HDL-cholesterol and higher triglyceride concentrations. These associations are consistent with other studies reporting association of this same variant with metabolic syndrome traits. None of the SNPs or haplotypes examined showed evidence of association with T2DM or IGH. We conclude that genetic variation in LMNA may play a modest role in susceptibility to metabolic syndrome and dyslipidemia in our population but is unlikely to be the gene on chromosome 1q21-q24 detected through linkage analysis contributing to risk of T2DM. 
